Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Gains from Sales and Divestitures: 2018

  • EyePoint Pharmaceuticals' Gains from Sales and Divestitures was N/A to $107,830 in Q2 2018 from the same period last year, while for Jun 2018 it was $107,830, marking a year-over-year change of. This contributed to the annual value of $107,830 for FY2018, which is N/A change from last year.
  • According to the latest figures from Q2 2018, EyePoint Pharmaceuticals' Gains from Sales and Divestitures is $107,830, which was up 123.10% from $48,332 recorded in Q1 2018.
  • EyePoint Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $107,830 during Q2 2018, with a 5-year trough of $48,332 in Q1 2018.
  • Moreover, its 1-year median value for Gains from Sales and Divestitures was $78,081 (2018), whereas its average is $78,081.